Ardelyx Inc. has announced the presentation of new real-world evidence studies on XPHOZAH® (tenapanor) at the American Society of Nephrology's Kidney Week. The data include results from the first prospective, observational cohort study evaluating the impact of an XPHOZAH-based regimen in patients with hyperphosphatemia on maintenance dialysis who were not adequately controlled with binder therapy. Findings demonstrated that XPHOZAH was effective in reducing serum phosphorus levels in real-world settings. Additionally, a cost-effectiveness analysis of tenapanor in Japanese patients with hyperphosphatemia on hemodialysis, presented by Kyowa Kirin Co., Ltd., concluded that tenapanor was cost-effective from the Japanese public healthcare payer's perspective. A real-world patient survey also indicated positive experiences with tenapanor, with reported improvements in serum phosphate levels, bowel movements, and reduced pill burden. The results have already been presented and are publicly available.